| Literature DB >> 16297621 |
Amedeo A Failli1, Jay S Shumsky, Robert J Steffan, Thomas J Caggiano, David K Williams, Eugene J Trybulski, Xiaoping Ning, Yeungwai Lock, Tarak Tanikella, David Hartmann, Peter S Chan, C H Park.
Abstract
Our efforts in seeking low molecular weight agonists of the antidiuretic peptide hormone arginine vasopressin (AVP) have led to the identification of the clinical candidate WAY-151932 (VNA-932). Further exploration of the structural requirements for agonist activity has provided another class of potent, orally active, non-peptidic vasopressin V2 receptor selective agonists exemplified by the 5,11-dihydro-pyrido[2,3-b][1,5]benzodiazepine as a candidate for further development.Entities:
Mesh：
Substances：
Year: 2005 PMID： 16297621 DOI： 10.1016/j.bmcl.2005.10.107
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN： 0960-894X Impact factor: 2.823